| Subject: | FDA Publishes Revised Labeling Requirements for Remicade (Infliximab) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 1 Sep 2004 - 10:00 am |
| FDA and Centocor, Inc. have announced that revisions have been made in the labeling (WARNINGS and ADVERSE REACTIONS listings) for the drug Remicade (infliximab). Remicade is used in the treatment of rheumatoid arthritis and Crohn's disease. Remicade works by blocking the body's immune system overproduction of the protein (TNF-alpha), which is an underlying cause of these diseases. The drug identifies and neutralizes the protein to relieve pain and symptoms of the diseases. The FDA reports that... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|
